SCHEMBL12066600

SCHEMBL12066600

OC(c1ccc(OC(F)(F)F)cc1)c1nc2cc(OC(F)F)ccc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 1/20 0.45
▸ MLKL Q8NB16 2/20 0.41
▸ KMT2A Q03164 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MTOR P42345 1/20 0.38
▸ PDE2A O00408 6/20 0.37
▸ TOP2A P11388 1/20 0.37
▸ TOP2B Q02880 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PKM P14618 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ RUNX1 Q01196 2/20 0.35
▸ EGLN1 Q9GZT9 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12066573 0.94 SCN10A (0.46) SCN10AMLKLKMT2AKDM4EGAA
SCHEMBL12065628 0.90 MLKL (0.47) MLKLKMT2AKDM4EPDE2ANPC1
SCHEMBL12065629 0.88 MLKL (0.41) SCN10AMLKLKMT2APDE2ANPC1
SCHEMBL14770707 0.87 SCN10A (0.48) SCN10AMLKLKMT2AGAAPDE2A
SCHEMBL12065285 0.87 SCN10A (0.46) SCN10AMLKLKMT2APDE2ATOP2A
SCHEMBL12066580 0.86 MLKL (0.43) SCN10AMLKLMTORPDE2ATOP2A
SCHEMBL12065245 0.86 ALPL (0.44) SCN10AMLKLKMT2AKDM4EGAA
SCHEMBL14770666 0.86 MLKL (0.59) SCN10AMLKLKMT2AKDM4EPDE2A
SCHEMBL14770699 0.86 MLKL (0.46) SCN10AMLKLKMT2AGAAPDE2A
SCHEMBL12065623 0.85 PRCP (0.43) SCN10AMLKLKMT2APDE2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US claimed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 — — EP claimed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US claimed
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed
WO-2011148956-A1 FUSED IMIDAZOLE DERIVATIVE トーアエイヨー株式会社 (JP) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A SCN10A 85/4885MLKL 2378/4885KMT2A 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback